SNP Consortium's Next Focus Could Be Drug Safety, Bristol Exec Suggests
The pharmaceutical industry SNP consortium's next focus should be on data that could help minimize side effects, Bristol-Myers Squibb Senior VP-Early Discovery & Applied Technology Elliot Sigal, MD/PhD, suggested.
You may also be interested in...
Drug manufacturers would not be able to use contracts with foreign distributors to prohibit reimportation of their products under the version of the prescription drug import amendments approved by the Agriculture Appropriations conference Oct. 5.
Bristol plans to expand into biologics development and manufacturing as part of its "external development" plans for the pharmaceutical division following the divestments of Clairol and Zimmer.
The SNP Consortium unveiled April 15 with funding from the Wellcome Trust and 10 major pharmaceutical companies completes over a year of discussions between the academic, industrial and government research communities over commercialization of the genomic research tool and pre-empts a potential flashpoint for the drug industry.